17
Apr

Galapagos and partner GlaxoSmithKline say their anti-inflammation candidate hit its mark in a mid-stage trial on psoriasis, a stroke of good news for a drug beset by developmental slipups.

…read more

Source: GlaxoSmithKline and Galapagos succeed in psoriasis after two setbacks

    

0 No comments